E-LIB Suche - Ergebnisse für: Bourdeau, I.

1

Regional differences in stage distribution and rates of tre..:

Panunzio, A. ; Tappero, S. ; Piccinelli, M....
European Urology. 83 (2023) - p. S1593 , 2023

2

The use of 18F-FDG PET/CT to guide management of adrenal hi..:

Parisien-La Salle, S. ; Morency-Potvin, P. ; Lord, M....
European Journal of Nuclear Medicine and Molecular Imaging. 48 (2020) 4 - p. 1250-1251 , 2020

Link: https://doi.org/10.1007/..

3

Abstract No. 185: Adrenal venous sampling in primary aldost..:

Chabrot, P. ; Bourdeau, I. ; Mazzuco, T....
Journal of Vascular and Interventional Radiology. 21 (2010) 2 - p. S71 , 2010

Link: https://doi.org/10.1016/..

4

Clinical and Biochemical Features of Seven Adult Adrenal Ga..:

Rondeau, G. ; Nolet, S. ; Latour, M....
The Journal of Clinical Endocrinology & Metabolism. 95 (2010) 7 - p. 3118-3125 , 2010

Link: https://doi.org/10.1210/..

5

Excess of infections due to a multi-drug sensitive Salmonel..:

Grandesso, F ; Jourdan-da Silva, N ; Le Hello, S...
Eurosurveillance. 13 (2008) 44 - p. , 2008

Link: https://doi.org/10.2807/..

6

Expression of Catenin family members CTNNA1, CTNNA2, CTNNB1..:

Smith, A. ; Bourdeau, I. ; Wang, J..
Molecular Brain Research. 135 (2005) 1-2 - p. 225-231 , 2005

Link: https://doi.org/10.1016/..

7

Cushing's syndrome variants secondary to aberrant hormone r..:

LACROIX, A ; BALDACCHINO, V ; BOURDEAU, I..
Trends in Endocrinology and Metabolism. 15 (2004) 8 - p. 375-382 , 2004

Link: https://doi.org/10.1016/..

8

Loss of Brain Volume in Endogenous Cushing's Syndrome and I..:

Bourdeau, I.
Journal of Clinical Endocrinology & Metabolism. 87 (2002) 5 - p. 1949-1954 , 2002

Link: https://doi.org/10.1210/..

9

Aberrant Membrane Hormone Receptors in Incidentally Discove..:

Bourdeau, I.
Journal of Clinical Endocrinology & Metabolism. 86 (2001) 11 - p. 5534-5540 , 2001

Link: https://doi.org/10.1210/..

10

Association between maternity care practitioner type and po..:

Bourdeau, Althea I. ; Harley, Kim G. ; Nguyen, Angela‐Maithy
Birth. 50 (2023) 4 - p. 923-934 , 2023

Link: https://doi.org/10.1111/..

11

What Is the Optimal Duration of Adjuvant Mitotane Therapy i..:

Basile, V ; Puglisi, S ; Altieri, B...
Basile , V , Puglisi , S , Altieri , B , Canu , L , Libe , R , Ceccato , F , Beuschlein , F , Quinkler , M , Calabrese , A , Perotti , P , Berchialla , P , Dischinger , U , Megerle , F , Baudin , E , Bourdeau , I , Lacroix , A , Loli , P , Berruti , A , Kastelan , D , Haak , H R , Fassnacht , M & Terzolo , M 2021 , ' What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question ' , Journal of Personalized Medicine , vol. 11 , no. 4 , 269 . https://doi.org/10.3390/jpm11040269. , 2021

Link: https://cris.maastrichtu..

12

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613. , 2021

Link: http://hdl.handle.net/23..

13

ENSAT registry-based randomized clinical trials for adrenoc..:

Crona, J ; Baudin, E ; Terzolo, M...
Crona , J , Baudin , E , Terzolo , M , Chrisoulidou , A , Angelousi , A , Ronchi , CL , Oliveira , CL , van Dijkum , E , Ceccato , F , Borson-Chazot , F , Reimondo , G , Tiberi , GAM , Ettaieb , H , Kiriakopoulos , A , Letizia , C , Kastelan , D , Osher , E , Yiannakopoulou , E , Arnaldi , G , Assie , G , Paiva , I , Bourdeau , I , Newell-Price , J , Nowak , KM , Romero , MT , de Martino , MC , Bugalho , MJ , Sherlock , M , Vantyghem , MC , Dennedy , MC , Loli , P , Rodien , P , Feelders , R A , de Krijger , R , Van Slycke , S , Aylwin , S , Morelli , V , Vroonen , L , Shafigullina , Z , Bancos , I , Trofimiuk-Muldner , M , Quinkler , M , Luconi , M , Kroiss , M , Naruse , M , Igaz , P , Mihai , R , Della Casa , S , Berruti , A , Fassnacht , M & Beuschlein , F 2021 , ' ENSAT registry-based randomized clinical trials for adrenocortical carcinoma ' , European Journal of Endocrinology , vol. 184 , no. 2 , pp. R51-R59 . https://doi.org/10.1530/EJE-20-0800. , 2021

Link: https://pure.eur.nl/en/p..

14

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613. , 2021

Link: http://hdl.handle.net/11..

15

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613. , 2021

Link: http://hdl.handle.net/11..